Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain
News
Enrollment has resumed for Aptinyx‘s Phase 2 clinical trial of NYX-2925, an oral small molecule designed to treat chronic pain in adults with fibromyalgia, the company announced. The study (NCT04147858) is ... Read more